BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright ©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Feb 16, 2026; 18(2): 116518
Published online Feb 16, 2026. doi: 10.4253/wjge.v18.i2.116518
Reduction of serum bilirubin levels after endoscopic biliary drainage in patients with extrahepatic biliary obstruction and its significance
Kosuru Sham Charan Naidu, Suprabhat Giri, Saroj Kanta Sahu, Dibya Lochan Praharaj, Bipadabhanjan Mallick, Preetam Nath, Swati Das, Sarat Chandra Panigrahi, Manoj Kumar Sahu, Anil Chandra Anand, Yogesh K Chawla, Subrat Kumar Acharya
Kosuru Sham Charan Naidu, Suprabhat Giri, Saroj Kanta Sahu, Dibya Lochan Praharaj, Bipadabhanjan Mallick, Preetam Nath, Sarat Chandra Panigrahi, Manoj Kumar Sahu, Anil Chandra Anand, Yogesh K Chawla, Subrat Kumar Acharya, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India
Swati Das, Department of Radiology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India
Co-first authors: Kosuru Sham Charan Naidu and Suprabhat Giri.
Author contributions: Naidu KSC and Giri S drafted the initial manuscript and they contributed equally to this manuscript as co-first authors; Mallick B, Nath P, and Anand AC contributed to the conception and design of the manuscript; Naidu KSC, Giri S, Sahu SK, Praharaj DL, Mallick B, Nath P, Das S, Panigrahi SC, Sahu MK, Anand AC, Chawla YK, and Acharya SK contributed to the literature review, analysis, data collection, interpretation, and critical revision of the initial manuscript. All authors approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Kalinga Institute of Medical Sciences (approval No. KIIT/KIMS/IEC/1331/2023).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Dataset available from the corresponding author at bipada.mallick@kims.ac.in.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bipadabhanjan Mallick, Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5 KIIT Road, Patia, Bhubaneswar 751024, Odisha, India. bipada.mallick@kims.ac.in
Received: November 14, 2025
Revised: December 3, 2025
Accepted: January 6, 2026
Published online: February 16, 2026
Processing time: 82 Days and 9 Hours
Abstract
BACKGROUND

Endoscopic retrograde cholangiopancreatography remains the primary modality for biliary decompression in extrahepatic biliary obstruction (EHBO). There are scarce data on the rate of fall in bilirubin after endoscopic biliary drainage (EBD) in EHBO.

AIM

To evaluate the rate and determinants of serum bilirubin decline after EBD in patients with EHBO and their impact on patient outcomes.

METHODS

This prospective observational study enrolled adults with EHBO and a serum total bilirubin level greater than 6 mg/dL who underwent endoscopic retrograde cholangiopancreatography from May 2023 to October 2024. Liver function tests were recorded at baseline and on days 1, 2, 7, and 15, and monthly thereafter. The primary outcome was the proportion of patients achieving a ≥ 50% decrease in bilirubin by day 7. Secondary outcomes included time to bilirubin < 3 mg/dL, predictors of biochemical response, need for reintervention, and 3-month mortality.

RESULTS

Among 101 patients, 60.4% had malignant EHBO. Overall, 80.2% achieved ≥ 50% bilirubin reduction by day 7, and 70.3% achieved bilirubin < 3 mg/dL by day 15. Benign etiology [adjusted odds ratio (aOR): 4.30; P = 0.038] and younger age (aOR: 0.95; P = 0.032) independently predicted an early response (day 7). Baseline bilirubin (aOR: 0.79; P < 0.001) and alkaline phosphatase levels (aOR: 1.002; P = 0.043) predicted bilirubin < 3 mg/dL by day 15. Reintervention was required in 15.8%, and 3-month mortality was 14.8%, predominantly in malignant EHBO. Failure to achieve > 50% reduction in bilirubin by day 7 was an independent predictor of reintervention, while failure to achieve bilirubin < 3 mg/dL by day 15 and acute kidney injury were independent predictors of mortality.

CONCLUSION

Failure to achieve ≥ 50% fall by day 7 predicts reintervention, while inability to reach bilirubin < 3 mg/dL by day 15 predicts mortality. Bilirubin kinetics following EBD serve as reliable indicators of drainage adequacy and short-term prognosis in EHBO.

Keywords: Endoscopic retrograde cholangiopancreatography; Extrahepatic biliary obstruction; Endoscopic biliary drainage; Malignant biliary obstruction; Choledocholithiasis

Core Tip: Early bilirubin kinetics provide a simple, reliable, and clinically actionable tool after endoscopic biliary drainage for extrahepatic biliary obstruction. A ≥ 50% fall in bilirubin by day 7 indicates adequate drainage and predicts lower need for reintervention, whereas failure should prompt early reassessment for stent dysfunction or incomplete drainage. Achieving a bilirubin < 3 mg/dL by day 15 is a strong indicator of recovery, particularly in malignant obstruction; failure to do so predicts higher short-term mortality. Baseline bilirubin, alkaline phosphatase levels, etiology, and presence of acute kidney injury should guide the intensity of monitoring. Routine incorporation of bilirubin kinetics can improve post-endoscopic retrograde cholangiopancreatography decision-making and outcomes.